AzTrials
AzTrials

Pre-diabetesNCT02030249

Sub-Study of the PREVIEW Study Australia

A study testing Low calorie diet administered from 0 to 2 months, High Protein / Low Glycaemic Index and Moderate Protein / High Glycaemic Index in people with Pre-diabetes and Obesity, run by University of Sydney at 3 sites in Australia.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of this study is to investigate possible enduring effects of a standard 2-month weight loss program on appetite regulation, bone homeostasis and muscle strength in younger and older adults, as well as the impact of differences in dietary composition during weight maintenance. Read more about this study

Who is it for?
Ages 25 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Pre-diabetes, Obesity
What is being tested?
Low calorie diet administered from 0 to 2 months, High Protein / Low Glycaemic Index and Moderate Protein / High Glycaemic Index
Could I receive a placebo?
No, everyone receives an active treatment
How many people
292 participants
Where
3 sitesAustralia
Study dates
Jan 2014to 31 Dec 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Age 25 - 45 years and 55 - 70 years
  • Overweight or obesity status BMI>25 kg/m2
  • Pre-diabetes. The criteria from WHO/IDF (International Diabetes Foundation) for assessing pre-diabetes will be used as the formal inclusion criteria, i.e. having: Impaired Fasting Glucose (IFG): Fasting venous plasma glucose concentration 5.6 - 6.9 mmol/l or Impaired Glucose Tolerance (IGT): Venous Plasma glucose concentration of 7.8 - 11.0 mmol/l at 2 h after oral administration of 75 g glucose (oral glucose tolerance test, OGTT), with fasting plasma glucose less than 7.0 mmol/l. Due to potential between-lab variation (local assessments), HbA1c is not used as an inclusion criteria in the screening.
  • Informed consent required
  • Ethnic group - No restrictions
  • Smoking - Smoking is allowed, provided subjects have not recently (within 1 month) changed habits. However, smoking status is monitored throughout the study and used as a confounding variable.
  • Motivation - Motivation and willingness to be randomized to any of the groups and to do his/hers best to follow the given protocol
  • Other - Able to participate at CID's during normal working hours.

Who cannot join

  • Based on interview and/or questionnaire, individuals with the following problems will be excluded:
  • Medical conditions as known by the subjects: Diabetes mellitus (other than gestational diabetes mellitus); Significant cardiovascular disease including current angina; myocardial infarction or stroke within the past 6 months; heart failure; symptomatic peripheral vascular disease; Systolic blood pressure above 160 mmHg and/or diastolic blood pressure above 100 mmHg whether on or off treatment for hypertension. If being treated, no change in drug treatment within last 3 months; Advanced chronic renal impairment; Significant liver disease e.g. cirrhosis (fatty liver disease allowed); Malignancy which is currently active or in remission for less than five years after last treatment (local basal and squamous cell skin cancer allowed); Active inflammatory bowel disease, celiac disease, chronic pancreatitis or other disorder potentially causing malabsorption; Previous bariatric surgery; Chronic respiratory, neurological, musculoskeletal or other disorders where, in the judgement of the investigator, participants would have unacceptable risk or difficulty in complying with the protocol (e.g. physical activity program); A recent surgical procedure until after full convalescence (investigators judgement); Transmissible blood-borne diseases e.g. hepatitis B, HIV; Psychiatric illness (e.g. major depression, bipolar disorder).
  • Medication: Use currently or within the previous 3 months of prescription medication that has the potential of affecting body weight or glucose metabolism such as glucocorticoids (but excluding inhaled and topical steroids; bronchodilators are allowed), psychoactive medication, epileptic medication, or weight loss medications (either prescription, over the counter or herbal). Low dose antidepressants are allowed if they, in the judgement of the investigator, do not affect weight or participation to the study protocol. Levothyroxine for treatment of hypothyroidism is allowed if the participant has been on a stable dose for at least 3 months.
  • Personal/Other: Engagement in competitive sports; Self-reported weight change of >5 % (increase or decrease) within 2 months prior to screening; Special diets (e.g. vegan, Atkins) within 2 months prior to study start. A lacto-vegetarian diet is allowed; Severe food intolerance expected to interfere with the study; Regularly drinking > 21 alcoholic units/week (men), or > 14 alcoholic units/week (women); Use of drugs of abuse within the previous 12 months; Blood donation or transfusion within the past 1 month before baseline or CID's; Self-reported eating disorders; Pregnancy or lactation, including plans to become pregnant within the next 36 months; No access to either phone or Internet (this is necessary when being contacted by the instructor's during the maintenance phase); Adequate understanding of national language; Psychological or behavioral problems which, in the judgement of the investigator, would lead to difficulty in complying with the protocol.
  • Laboratory screening: If all of the above criteria are satisfied, the participant is eligible for a glucose tolerance test (blood at 0 and 120 mins), and blood glucose concentrations are analyzed immediately (Haemocue). In addition full blood count, urea, and electrolytes may be analyzed as a further safety evaluation.
  • ONLY IF the glucose tolerance test meets the entry criteria for the study, the remaining samples are sent to the local laboratory for a safety check, with the following exclusion criteria: Hemoglobin concentration below local laboratory reference values (i.e. anemia); Creatinine >1.5 times Upper Limit of Normal (local laboratory reference values); Alanine Transaminase (ALT) and/or Aspartate Transaminase (AST) >3 times the Upper Limit of Normal (local laboratory reference values); Or any other significant abnormality on these tests which in the investigators opinion may be clinically significant and require further assessment.
  • Electrocardiography (ECG). Any abnormality which in the opinion of the investigator might indicate undiagnosed cardiac disease requiring further assessment (e.g. significant conduction disorder, arrhythmia, pathological Q waves). This is done in adults 55-70 years of age.
  • After LCD phase (in adults): Failure to reach at least 8% weight reduction during the LCD phase. This leads to exclusion from the intervention.

Trial locations and contacts

3 sites in 1 country.

Australia3 sites
  • The University of Sydney

    Camperdown, New South Wales, 2006

  • Garvan Institute of Medical Research

    Darlinghurst, Sydney, New South Wales, 2010

  • Prince of Wales Hospital

    Randwick, Sydney, New South Wales, 2031

Other trials in Australia

About this study

Official title: Sub-Study of the PREVIEW Study Australia: Effects of Weight Loss on Appetite, Bone Mass and Muscle Strength

The aim of this study is to investigate possible enduring effects of a standard 2-month weight loss program on appetite regulation, bone homeostasis and muscle strength in younger and older adults, as well as the impact of differences in dietary composition during weight maintenance.

Read the detailed description

This sub-study consists of 2 parts:

PART 1. Durability of changes in appetite and appetite-regulating hormones after weight loss in overweight or obese pre-diabetic adults: impact of diet during weight maintenance.

A major reason for the failure of many lifestyle-based weight loss attempts is that the body responds to energy restriction and weight loss with a series of adaptive responses that prevent ongoing weight loss and promote weight regain (Sainsbury and Zhang 2010; Sainsbury and Zhang 2012). This 'famine reaction' includes increased appetite and alterations in circulating concentrations of gut-derived hormones that tend to stimulate appetite and promote fat accumulation. Recent evidence suggests that these alterations are sustained for as long as the lower body weight is maintained (Sumithran et al 2011). This finding - if validated in other populations - has enormous implications for clinical practice. For instance, if we know for certain that the weight loss-induced increase in appetite cannot be reversed without weight regain, or if we can identify those individuals for whom the increase in appetite does not subside, then multiple fruitless and heartbreaking efforts to lose excess weight via lifestyle interventions could be circumvented, and those individuals could immediately be channelled into more aggressive - albeit still imperfect - treatment options (i.e. long-term appetite-suppressing medications, bariatric surgery). If, on the other hand, we know that the increased appetite following weight loss does subside following a period of weight maintenance at the lower weight, or if we could identify those individuals for whom this is possible, then this information could be used to promote compliance with weight maintenance strategies after weight loss, with patient messages such as; "Keeping weight off will be difficult in the beginning, but don't give up because it will likely become easier with time".

A substantial body of research shows that a diet that is higher in protein (Westerterp-Plantenga et al 2004) and lower in glycaemic index (Brand-Miller et al 2002) than the diet that is conventionally recommended for health may help people to maintain a lower body weight post weight loss, and that this benefit may occur by reducing the drive to eat. These findings raise the possibility that a higher protein and lower glycaemic index weight maintenance diet could be used to reduce the intensity of the famine reaction in overweight or obese people after completion of weight loss diets, thereby improving their likelihood of keeping the weight off. While there is ample research showing the benefits of a higher protein diet for reducing appetite, enhancing weight loss and preserving lean body mass loss when applied during energy restricted weight loss programs, as recently reviewed (Soenen et al 2013), there is relatively little work to date about the emerging benefits of a higher protein diet applied during a weight maintenance program after weight loss. The importance of this Sub-Study (Part 1) is that it not only seeks to confirm a controversial new finding that has potentially enormous implications for the clinical management of overweight and obesity (Sumithran et al 2011), it also investigates the potential benefit of a higher protein and lower GI diet - applied during the weight maintenance phase after a standardized weight loss program - to prevent the apparently permanent increase in appetite that overweight and obese people have been reported in one study (Sumithran et al 2011) to experience in response to weight loss.

Part 1 Hypothesis:

  • Both overweight and obese individuals will demonstrate increases in appetite and corresponding changes in appetite-regulating hormones in response to a standardized low calorie diet weight loss program, and these effects will be normalized within 4-10 months on a weight maintenance program in overweight but not in obese individuals.
  • In both overweight and obese individuals, a higher protein and lower glycaemic index weight maintenance diet after a weight-reducing diet will improve normalisation of appetite and appetite-regulating hormones compared to a moderate protein and moderate glycaemic index weight maintenance diet.

Part 1 Aim:

  • To determine fasting appetite and fasting circulating concentrations of appetite-regulating hormones (ghrelin and peptide YY) after a 2-month standardized low calorie diet in overweight and obese pre-diabetic adults, and to determine whether any effects are attenuated by 4 and 10 months on one of two different weight maintenance programs differing in protein content and glycaemic index.

PART 2. Effect of weight loss on bone homeostasis and muscle strength in younger and older overweight or obese pre-diabetic adults: impact of diet during weight maintenance on long-term durability of effects.

While it is generally recognised that losing excess weight helps to prevent disease development in younger adults, there is some controversy as to whether weight loss programs are indicated for the management of overweight or obesity in older adults, and if so, at what body mass index such programs should be implemented (Chapman 2008). It is noteworthy that weight loss via voluntary or involuntary means in older adults is linked to reduced function, reduced quality of life and increased mortality (Chapman 2008). The reason for this relationship is not clear, but one possibility is that weight loss programs can lead to significant loss of bone and lean tissues under certain circumstances (e.g. inadequate dietary protein, inadequate exercise), and it is unknown if these losses are recuperated. Given that reductions in bone density and lean body mass are risk factors for fractures and falls in older adults, changes in body composition in response to weight loss efforts in older adults could inadvertently produce negative effects. In light of the established role of dietary protein in the maintenance of lean tissues such as bone and muscle in older people or in response to weight loss (Westerterp-Plantenga et al 2012), the PREVIEW trial offers an invaluable opportunity to investigate the effects of a standardised weight loss program on bone homeostasis and muscle function (strength) in younger and older adults, as well as the impact of differences in diet during weight maintenance in attenuating any such effects.

Part 2 Hypothesis:

  • That a 2-month standardized low calorie diet weight loss program leads to reductions in bone mass and muscle strength in both younger and older adults, particularly in older adults, and that these parameters return towards baseline values within 3 years in younger but not in older adults.
  • That a higher protein weight-maintenance diet improves the restoration of bone mass and muscle strength after weight loss in both younger and older adults.

Part 2 Aim:

  • To measure bone mass, bone turnover and muscle strength in younger (25-45 year old) and older (55-70 year old) adults before and after a standardized 2-month weight loss program, as well as at 6, 12, 24 and 36 months after commencement of the weight loss program.
  • To compare the effects of two different weight maintenance programs differing in protein content on the restoration of bone homeostasis and muscle strength after a standardized 2-month weight loss diet. The weight maintenance programs are of 10 months' duration and are administered immediately after the 2-month weight loss program.
Being tested
Low calorie diet administered from 0 to 2 months, High Protein / Low Glycaemic Index, Moderate Protein / High Glycaemic Index
Keywords
Pre-diabetes, Obesity, Low calorie diet, Diet - reducing, Appetite, Visual analogue scale, Ghrelin, Peptide YY, Bone mass, Bone turnover, Muscle strength
Medical subject headings
Glucose Intolerance, Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Low calorie diet administered from 0 to 2 monthsBehavioural

    Also called 2-month low calorie diet, 2-month standardized low calorie diet, 2-month Cambridge Diet, 2-month low energy diet

    The 2-month low calorie diet is administered from the 0 months to the 2 months time point. It is designed to elicit a weight loss of 8% of initial body weight. Please see parent study for further intervention details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview\&rank=1

  • High Protein / Low Glycaemic IndexBehavioural

    Please see description of the Arm by the same name.

  • Moderate Protein / High Glycaemic IndexBehavioural

    Please see description of the Arm by the same name.

Study groups in NCT02030249
Study groupRoleWhat they receive
High Protein / Low Glycaemic IndexExperimentalA 10-month weight maintenance diet, administered from the 2-month to the 12-month time point, where protein intake is 25% of energy intake, carbohydrate intake is 45% of energy intake, dietary glycaemic index is < 55. Please see parent study for further Arm details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview\&rank=1
Receives: Behavioral: Low calorie diet administered from 0 to 2 months; Behavioral: High Protein / Low Glycaemic Index
Moderate Protein / High Glycaemic IndexActive comparatorA 10-month weight maintenance diet, administered from the 2-month to the 12-month time point, where protein intake is 15% of energy intake, carbohydrate intake is 55% of energy intake, dietary glycaemic index is > 65. Please see parent study for further Arm details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview\&rank=1
Receives: Behavioral: Low calorie diet administered from 0 to 2 months; Behavioral: Moderate Protein / High Glycaemic Index

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Fasting appetite

    Previous research has shown that a weight reducing diet increases appetite in the fasting state. There is some suggestion that this diet-induced increase in appetite is sustained even after following a weight maintenance diet for 12 months. We will assess fasting appetite using visual analogue scales after commencement of the standardized weight loss diet. This primary outcome will demonstrate whether the weight-loss-induced increase in fasting appetite that is anticipated at completion of the diet will be normalized by the 12 month time point, and whether the type of weight maintenance diet (High Protein / Low Glycaemic Index versus Moderate Protein / High Glycaemic Index) influences this.

    Measured: 12 months

  2. Bone mass

    We will assess bone mineral density and bone mineral content in the lumbar spine and hip (or wrist for people in whom arthritis interferes with the reading) via dual energy X-ray absorptiometry (DXA) at 2 months after commencement of the standardized weight loss diet. This primary outcome will help determine whether there is a difference between younger and older participants with respect to changes in bone mass with weight reduction, and whether the type of weight maintenance diet influences this.

    Measured: 2 months

Secondary outcomes (34)
  1. Fasting appetite

    Measured: 0 months

  2. Fasting appetite

    Measured: 2 months

  3. Fasting appetite

    Measured: 6 months

  4. Fasting appetite

    Measured: 24 months

  5. Fasting appetite

    Measured: 36 months

  6. Fasting plasma concentrations of gut-derived appetite-regulating hormones

    Previous research has shown that a weight reducing diet alters fasting plasma concentrations of gut-derived appetite regulating hormones in a way that would be expected to increase appetite (i.e. increased ghrelin and decreased peptide YY). We will assess fasting plasma concentrations of gut-derived appetite-regulating hormones (ghrelin and peptide YY).

    Measured: 0 months

  7. Fasting plasma concentrations of gut-derived appetite-regulating hormones

    Measured: 2 months

  8. Fasting plasma concentrations of gut-derived appetite-regulating hormones

    Measured: 6 months

  9. Fasting plasma concentrations of gut-derived appetite-regulating hormones

    Measured: 12 months

  10. Fasting plasma concentrations of gut-derived appetite-regulating hormones

    Measured: 24 months

  11. Fasting plasma concentrations of gut-derived appetite-regulating hormones

    Measured: 36 months

  12. Bone mass

    Measured: 0 months

  13. Bone mass

    Measured: 2 months

  14. Bone mass

    Measured: 6 months

  15. Bone mass

    Measured: 24 months

  16. Bone mass

    Measured: 36 months

  17. Bone turnover

    The bone turnover markers to be measured are serum procollagen type-I N-propeptide (P1NP, a marker of bone formation) and serum C-telopeptide of type-I collagen (CTX, a marker of bone resporption). This outcome will enable us to determine whether there is a difference between younger and older participants with respect to changes in bone turnover with weight reduction, and whether the type of weight maintenance diet (High Protein / Low Glycaemic Index versus Moderate Protein / High Glycaemic Index) influences this. This outcome is important because DXA scanning to assess bone mass can result in artefactual results in people with obesity or who are undergoing changes in body fat mass, as will be the case in this trial.

    Measured: 0 months

  18. Bone turnover

    Measured: 2 months

  19. Bone turnover

    Measured: 6 months

  20. Bone turnover

    Measured: 12 months

  21. Bone turnover

    Measured: 24 months

  22. Bone turnover

    Measured: 36 months

  23. Modulators of bone turnover

    Pending funding availability: serum 25-OH vitamin D, serum parathyroid hormone, serum calcium, serum phosphate, serum albumin and serum creatine.

    Measured: 0 months

  24. Modulators of bone turnover

    Measured: 2 months

  25. Modulators of bone turnover

    Measured: 6 months

  26. Modulators of bone turnover

    Measured: 12 months

  27. Modulators of bone turnover

    Measured: 24 months

  28. Modulators of bone turnover

    Measured: 36 months

  29. Muscle (handgrip) strength

    Muscle (handgrip) strength will be determined with a handheld dynamometer. This secondary outcome measure aims to determine whether the standardized weight loss diet induces changes in muscle strength, and whether there is any differential effect in younger versus older participants.

    Measured: 0 months

  30. Muscle (handgrip) strength

    Measured: 2 months

  31. Muscle (handgrip) strength

    If the investigators see a change from baseline in muscle (handgrip) strength after the low calorie diet in the younger or older participants, then they will measure muscle (handgrip) strength again at 6 months, to determine whether any such change from baseline is maintained after the two different weight maintenance programs. This secondary outcome will enable determination of whether any effects of the standardized low calorie diet on muscle (handgrip) strength are sustained at 6 months, and whether the type of weight maintenance diet (High Protein / Low Glycaemic Index versus Moderate Protein / High Glycaemic Index) influences this.

    Measured: 6 months

  32. Muscle (handgrip) strength

    Measured: 12 months

  33. Muscle (handgrip) strength

    Measured: 24 months

  34. Muscle (handgrip) strength

    Measured: 36 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Jan 2014 (estimated)
  2. Study startJan 2014
  3. Primary completionJun 2018
  4. Study completion31 Dec 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
292 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02030249
Sponsor's protocol ID
2013/535 - SUB-STUDY
Other IDs
KBBE-CALL- 6-Nr. 312057
Status last verified
Apr 2021
First submitted
12 Dec 2013
Last updated
30 Apr 2021
Results posted
No
Data monitoring committee
No

Publications

  • Sainsbury A, Zhang L. Role of the arcuate nucleus of the hypothalamus in regulation of body weight during energy deficit. Mol Cell Endocrinol. 2010 Mar 25;316(2):109-19. doi: 10.1016/j.mce.2009.09.025. Epub 2009 Oct 12.

    PubMed 19822185
  • Sainsbury A, Zhang L. Role of the hypothalamus in the neuroendocrine regulation of body weight and composition during energy deficit. Obes Rev. 2012 Mar;13(3):234-57. doi: 10.1111/j.1467-789X.2011.00948.x. Epub 2011 Nov 10.

    PubMed 22070225
  • Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011 Oct 27;365(17):1597-604. doi: 10.1056/NEJMoa1105816.

    PubMed 22029981
  • Westerterp-Plantenga MS, Lejeune MP, Nijs I, van Ooijen M, Kovacs EM. High protein intake sustains weight maintenance after body weight loss in humans. Int J Obes Relat Metab Disord. 2004 Jan;28(1):57-64. doi: 10.1038/sj.ijo.0802461.

    PubMed 14710168
  • Brand-Miller JC, Holt SH, Pawlak DB, McMillan J. Glycemic index and obesity. Am J Clin Nutr. 2002 Jul;76(1):281S-5S. doi: 10.1093/ajcn/76/1.281S.

    PubMed 12081852
  • Soenen S, Martens EA, Hochstenbach-Waelen A, Lemmens SG, Westerterp-Plantenga MS. Normal protein intake is required for body weight loss and weight maintenance, and elevated protein intake for additional preservation of resting energy expenditure and fat free mass. J Nutr. 2013 May;143(5):591-6. doi: 10.3945/jn.112.167593. Epub 2013 Feb 27.

    PubMed 23446962
  • Chapman IM. Obesity in old age. Front Horm Res. 2008;36:97-106. doi: 10.1159/000115358.

    PubMed 18230897
  • Westerterp-Plantenga MS, Lemmens SG, Westerterp KR. Dietary protein - its role in satiety, energetics, weight loss and health. Br J Nutr. 2012 Aug;108 Suppl 2:S105-12. doi: 10.1017/S0007114512002589.

    PubMed 23107521
  • Buso MEC, Seimon RV, McClintock S, Muirhead R, Atkinson FS, Brodie S, Dodds J, Zibellini J, Das A, Wild-Taylor AL, Burk J, Fogelholm M, Raben A, Brand-Miller JC, Sainsbury A. Can a Higher Protein/Low Glycemic Index vs. a Conventional Diet Attenuate Changes in Appetite and Gut Hormones Following Weight Loss? A 3-Year PREVIEW Sub-study. Front Nutr. 2021 Mar 22;8:640538. doi: 10.3389/fnut.2021.640538. eCollection 2021.

    PubMed 33829034

Questions about this trial

What is this clinical trial studying?

A study testing Low calorie diet administered from 0 to 2 months, High Protein / Low Glycaemic Index and Moderate Protein / High Glycaemic Index in people with Pre-diabetes and Obesity, run by University of Sydney at 3 sites in Australia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 30 Apr 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Fasting appetite (time frame: 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02030249, which also lists 9 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Apr 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in